Roche Pays Hansoh $400 Million Upfront in an ADC Deal Worth More Than $15 Billion
Hansoh disclosed the deal on October 19, 2026, while Hong Kong was closed for a holiday. Its upfront payment is more than twice the largest Hansoh has received before, and the shares rose as much as 7.69% when trading resumed.
- Roche will pay Hansoh $400 million upfront and $110 million on the deal's first anniversary, with more than $15 billion in possible milestone payments plus tiered royalties.
- The deal covers antibody-drug conjugates (ADCs), cancer drugs that attach a toxic payload to an antibody: two early Hansoh programs and further programs on targets Roche proposes.
- Hansoh keeps mainland China, Hong Kong, Macau and Taiwan; Roche takes the rest of the world after early human trials.
Roche agreed to pay Hansoh Pharmaceutical $400 million upfront and $110 million on the first anniversary of a licensing deal for antibody-drug conjugates (ADCs), cancer medicines that attach a toxic payload to an antibody so it reaches tumor cells. Hansoh can also earn more than $15 billion in development, regulatory and sales milestones plus tiered royalties. The companies signed on Saturday, October 17, 2026, and Hansoh disclosed the deal in a Hong Kong exchange filing on Monday, October 19; the first headline reached the MoveSurge news feed at 07:56:00 ET that day.
The deal covers two Hansoh ADCs that have not yet been tested in people and several more programs aimed at targets that Roche proposes, all built on Hansoh's ADC technology. Hansoh runs development through the first global phase of human trials. Roche then develops the drugs outside mainland China, Hong Kong, Macau and Taiwan, which Hansoh keeps, and Hansoh can choose to share in up to two programs outside those markets.
| Term | Detail |
|---|---|
| Upfront payment | $400 million |
| Payment on first anniversary | $110 million |
| Possible milestones | More than $15 billion |
| Royalties | Tiered, on sales |
| Hansoh's territory | Mainland China, Hong Kong, Macau, Taiwan |
| Roche's territory | Rest of the world, after global Phase Ia |
Hansoh's largest deal by a wide margin
Hansoh has licensed drugs to large Western companies before, but never on this scale. Its earlier deals carried upfront payments of $80 million to $185 million and maximum values of about $1.5 billion to $2.3 billion each. The new upfront payment is more than twice its previous largest, from GSK in December 2023, and the possible milestones alone are several times larger than any earlier Hansoh deal.
| Partner and drug | Date | Upfront | Milestones, up to |
|---|---|---|---|
| GSK, HS-20089 (B7-H4 ADC) | October 2023 | $85 million | $1.485 billion |
| GSK, HS-20093 (B7-H3 ADC) | December 2023 | $185 million | $1.525 billion |
| Merck, HS-10535 (oral GLP-1) | December 2024 | $112 million | $1.9 billion |
| Roche, HS-20110 (CDH17 ADC) | October 2025 | $80 million | $1.45 billion |
| Avere, HS-20118 (oral, psoriasis) | July 2026 | $120 million | $2.18 billion |
| Roche, ADC programs | October 2026 | $400 million, plus $110 million after a year | More than $15 billion |
This is also the second time in a year that Roche has licensed ADCs from Hansoh. In October 2025 it took rights to HS-20110, an ADC aimed at the CDH17 protein, for $80 million upfront. That deal bought one named drug. This one pays for programs aimed at targets Roche will pick, so Roche is paying mainly for Hansoh's ability to design ADCs. By headline value it still trails AstraZeneca's January 2026 deal with CSPC, which was worth up to $18.5 billion, the largest Chinese out-licensing deal so far.
How the shares reacted
Hong Kong's stock market was closed on Monday, October 19, for the Chung Yeung Festival holiday, so Hansoh shares could not trade on the news until Tuesday. In Tuesday morning trading Hansoh rose as much as 7.69% to HK$34.18 from its October 16 close of HK$31.74, and it was up 7.50% at the midday break while the Hang Seng index was down 0.95%. Roche shares closed 0.24% higher in Zurich on Monday.
How much is Roche paying Hansoh?
Roche pays $400 million upfront and $110 million on the first anniversary of the deal. Hansoh can also earn more than $15 billion in development, regulatory and commercial milestones, plus tiered royalties on sales.
What drugs are in the Roche and Hansoh deal?
Antibody-drug conjugates for cancer: two Hansoh ADCs that have not yet entered human trials and several more programs aimed at targets Roche proposes. The companies have not named the molecules or their targets.
Why did Hansoh stock rise on October 20, 2026?
It was the first trading day after Hansoh disclosed the Roche deal, because Hong Kong was closed on October 19. The shares rose as much as 7.69% to HK$34.18 in the morning session.
Sources
-
Hansoh Pharmaceutical announcement: collaboration and license agreement with F. Hoffmann-La Roche
— Hansoh Pharmaceutical via HKEXnews
Signed October 17, 2026: $400 million upfront, $110 million on first anniversary, more than $15 billion in milestones, tiered royalties; two preclinical ADCs plus Roche-proposed targets; territory split and opt-in rights.
-
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion
— Reuters via TradingView
Independent report of the Roche-Hansoh deal worth more than $15 billion.
-
Roche returns to China's ADC powerhouse Hansoh with $15B biobucks pact
— Fierce Biotech
Deal terms and its place after Roche's October 2025 Hansoh ADC license.
-
Hansoh shares jump after Roche deal
— Jiemian
Hansoh rose 7.69% to HK$34.18 in Tuesday morning trading.
Never miss the next market-moving story
Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes price moves after the news, search, watchlists, alerts and research tools.
Create free accountGo real time Watch live headlines -- free